ReviewOncotarget2017
Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment.
Review in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Microbiota composition effect on immunotherapy outcomes in colorectal cancer patients: A systematic review.PloS one · 2024Pooled it
- Microbial Diversity and Composition Is Associated with Patient-Reported Toxicity during Chemoradiation Therapy for Cervical Cancer.International journal of radiation oncology, biology, physics · 2020Trial
- Clinical Evidence for Microbiome-Based Strategies in Cancer Immunotherapy: A State-of-the-Art Review.Medicina (Kaunas, Lithuania) · 2025Review
- The microbiome as a therapeutic co-driver in melanoma immuno-oncology.Frontiers in medicine · 2025Review
- Impact of Infections in Patients Receiving Pembrolizumab-Based Therapies for Non-Small Cell Lung Cancer.Cancers · 2022Article
- Review
- Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy.Frontiers of medicine · 2022Review
- Hepatitis B Virus Reactivation in Cancer Patients Undergoing Immune Checkpoint Inhibitors Therapy: A Systematic Review.Journal of Cancer · 2022Review
- Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer.Frontiers in immunology · 2022Review
- Treatment of inflammatory bowel disease: Potential effect of NMN on intestinal barrier and gut microbiota.Current research in food science · 2022Article
- The role of microbiota in immunotherapy outcomes in colorectal cancer patients: A protocol for a systematic review.PloS one · 2022Article
- Hepatocellular Carcinomas with Granulomatous Inflammation In Tumor Stroma: Clinicopathologic Characteristics.Turk patoloji dergisi · 2022Article
- Influence of Microbiome and Antibiotics on the Efficacy of Immune Checkpoint Inhibitors.Cureus · 2021Review
- Inhibition of PD-1 Protects against TNBS-Induced Colitis via Alteration of Enteric Microbiota.BioMed research international · 2021Article
- The interaction between gut microbiome and anti-tumor drug therapy.American journal of cancer research · 2021Review
- Gut microbiota regulate tumor metastasis via circRNA/miRNA networks.Gut microbes · 2020Article
- Endpoints of active periodontal therapy.Journal of clinical periodontology · 2020Article
- The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy.Vaccines · 2020Article
- Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions.Journal of immunology research · 2020Review
- Microbiome within Primary Tumor Tissue from Renal Cell Carcinoma May Be Associated with PD-L1 Expression of the Venous Tumor Thrombus.Advances in urology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune Checkpoint Inhibitors (ICIs) are improving the survival of cancer patients, however only the 20-30% of treated patients present clinical benefits. Toxicity represents the major cause of reduced dosage, delayed drug administration and therapy discontinuation. Hence in the context of multiple treatment possibilities, the identification of predictive markers of response and toxicity is a challenging approach for drug selection in order to obtain the best clinical benefit while minimizing the side effects. The loss of the protective function of intestinal barriers that interacts with the environment measured as increased intestinal permeability and the changes occurring in the microbiota composition have been proposed as a mechanism potentially explaining the pathogenesis of immune related toxicity.In this review we discuss the new perspectives on the involvement of PD-1 and PDL-1 in the cross talk between gut microbiota and immune fitness and how gut microbiota impacts on the efficacy of anti-PD-1 and anti-PDL-1 treatments in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.